Abbott (ABT) slips as results, guidance barely meet consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Abbott forecasts 2024 earnings largely below estimates, shares down
January 24, 2024 7:34 AM EST(Reuters) -Abbott Laboratories on Wednesday forecast 2024 profit largely below Wall Street estimates despite meeting quarterly earnings expectations, sending the medical device maker's shares down 2.5% in premarket trading.
Expectations around performance of medical device makers have increased over the last one month after health insurers flagged higher medical costs earlier this month as people, especially older adults, go back for medical procedures they had delayed during the pandemic.
Abbott's forecast also follows strong... More
Abbott (ABT) Reports In-Line Q4 EPS, Offers Guidance
January 24, 2024 7:31 AM ESTAbbott (NYSE: ABT) reported Q4 EPS of $1.19, in-line with the analyst estimate of $1.19. Revenue for the quarter came in at $10.24 billion versus the consensus estimate of $10.17 billion.
GUIDANCE:
Abbott sees FY2024 EPS of $4.50-$4.70, versus the consensus of $4.63.
For earnings history and earnings-related data on Abbott (ABT) click here.
... MoreAbbott Labs (ABT) PT Raised to $136 at UBS
January 22, 2024 7:52 AM ESTUBS analyst Danielle Antalffy raised the price target on Abbott Labs (NYSE: ABT) to $136.00 (from $122.00) while maintaining a Buy rating.... More

